Centus Biotherapeutics Limited
Quick facts
Phase 3 pipeline
- FKB238 (bevacizumab) · Oncology
FKB238 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: